Systematic review uncovers AI's role in improving personalized cancer treatment outcomes, suggesting future research directions.
Big data analytics’ incorporation into customized cancer care is a revolutionary development in medical science. Using knowledge from genomic sequencing, electronic health records (EHRs), clinical trial databases, and social determinants of health, this systematic review investigates the relationship between artificial intelligence (AI), machine learning, and big data analysis in customizing cancer treatments for each patient. The study highlights how AI‐driven prediction models might improve treatment outcomes, reduce side effects, and increase patient safety by synthesizing insights from the last 10 years of academic research. A systematic literature review that follows PRISMA guidelines and includes both quantitative and qualitative evaluations of academic publications is among the key approaches. The findings show that multiomics approaches, which combine transcriptomics, proteomics, metabolomics, and genomics, are becoming increasingly important for customized medicine. Real‐time data analytics and wearable technology are also noted as promising resources for prompt responses. Notwithstanding obstacles, including data heterogeneity, moral dilemmas, and validation problems, the results highlight how crucial AI is to treating tumor complexity and developing precision medicine. In order to improve regulatory frameworks, promote interdisciplinary collaboration, and optimize AI applications in cancer treatment planning, the study concludes by suggesting future research areas. For scientists, physicians, and legislators hoping to transform cancer treatment using big data analytics–driven tailored medicine, this review provides insightful information.
No takes yet. Share an insight, caveat, or question.
Ahmed et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: